Regulation of NOXO1 Activity through Reversible Interactions with p22^{phox} and NOXA1

Sujit Dutta*, Katrin Rittinger*
National Institute for Medical Research, Medical Research Council, London, United Kingdom

Abstract
Reactive oxygen species (ROS) have been known for a long time to play important roles in host defense against microbial infections. In addition, it has become apparent that they also perform regulatory roles in signal transduction and cell proliferation. The source of these chemicals are members of the NOX family of NADPH oxidases that are found in a variety of tissues. NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22^{phox} for maximal activity. Unlike NOX2, the phagocytic NADPH oxidase whose activity is tightly repressed in the resting state, NOX1 produces superoxide constitutively at low levels. These levels can be further increased in a stimulus-dependent manner, yet the molecular details regulating this activity are not fully understood. Here we present the first quantitative characterization of the interactions made between the cytosolic regulators NOXO1 and NOXA1 and membrane-bound p22^{phox}. Using isothermal titration calorimetry we show that the isolated tandem SH3 domains of NOXO1 bind to p22^{phox} with high affinity, most likely adopting a superSH3 domain conformation. In contrast, complex formation is severely inhibited in the presence of the C-terminal tail of NOXO1, suggesting that this region competes for binding to p22^{phox} and thereby contributes to the regulation of superoxide production. Furthermore, we provide data indicating that the molecular details of the interaction between NOXO1 and NOXA1 is significantly different from that between the homologous proteins of the phagocytic oxidase, suggesting that there are important functional differences between the two systems. Taken together, this study provides clear evidence that the assembly of the NOX1 oxidase complex can be regulated through reversible protein-protein interactions.

Introduction
Superoxide is generated in a variety of tissues by NADPH oxidase (NOX) enzymes. It is an intermediate in the formation of reactive oxygen species (ROS), which have been implicated in a number of cellular functions including host defence, apoptosis, signalling and cell proliferation [1–7].

The first member of the NOX protein family to be identified was the phagocytic NADPH oxidase, whose gp91^{phox} subunit is now referred to as NOX2. This enzyme is primarily found in phagocytes where it plays a fundamental role in host defence against microbial infections [8–10]. This microbicidal activity was increased in a stimulus-dependent manner, yet the molecular details regulating this activity are not fully understood. Here we present the first quantitative characterization of the interactions made between the cytosolic regulators NOXO1 and NOXA1 and membrane-bound p22^{phox}. Using isothermal titration calorimetry we show that the isolated tandem SH3 domains of NOXO1 bind to p22^{phox} with high affinity, most likely adopting a superSH3 domain conformation. In contrast, complex formation is severely inhibited in the presence of the C-terminal tail of NOXO1, suggesting that this region competes for binding to p22^{phox} and thereby contributes to the regulation of superoxide production. Furthermore, we provide data indicating that the molecular details of the interaction between NOXO1 and NOXA1 is significantly different from that between the homologous proteins of the phagocytic oxidase, suggesting that there are important functional differences between the two systems. Taken together, this study provides clear evidence that the assembly of the NOX1 oxidase complex can be regulated through reversible protein-protein interactions.
Figure 1. Schematic representation of the domain structures of p47phox, NOXO1, p67phox and NOXA1. (A) Predicted domain structures of NOXO1 and NOXA1 in comparison to p47phox and p67phox, respectively. Human and mouse constructs used in this study are illustrated by black lines. Mouse constructs are identical in length unless otherwise stated in brackets. The autoinhibitory region (AIR) and proline rich region (PPR) are
that the tandem SH3 domains adopt an unusual, novel conformation, termed the superSH3 domain, in which the two SH3 domains co-operate to form a single ligand binding site that is occupied by a non-canonical motif located in the N-terminal portion of the polybasic region [22,24]. Extensive, additional contacts are made between the polybasic region and the reminder of p47phox outside of the core superSH3 domain ligand binding site that are important to enforce the resting state. Multiple serine residues within this polybasic region become phosphorylated upon activation, a process that weakens the intramolecular interactions and instead favours complex formation with the membrane-bound cytochrome. Additionally, a proline-rich region in the C-terminal portion of p47phox mediates the interaction with p67phox via specific recognition of its C-terminal SH3 domain. This interaction, which occurs with an unusually high affinity of 20 nM [25–27], is absolutely required for translocation of p67phox to the membrane.

Although NOX1 was the first homologue of the phagocytic oxidase to be identified, its precise physiological function remains somewhat controversial although there is support for a role in host cell defense in the gastrointestinal tract and cell proliferation [11,28–31]. For optimal activity NOX1 has been shown to require p22phox, Rac and two regulatory subunits, termed NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1) that have been identified based on their homology with p47phox and p67phox, respectively [32–37]. The main difference between p47phox and NOX1 is the absence of the polybasic region that is important for autoinhibition and the regulation of the interaction with p22phox. NOXA1 contains a TPR (tetratricopeptide), PB1 (Phox and Bem1) and a carboxy-terminal SH3 domain, similar to p67phox but lacks a centrally located SH3 domain (Figure 1).

The lack of the autoinhibitory region in NOX1 combined with the observations that NOX1 produces superoxide constitutively at low levels and that a stimulus-induced increase in superoxide production only occurs in certain human cell types, has led to the suggestion that NOXO1 is permanently associated with p22phox and that its activity is not regulated by phosphorylation or other signalling events that may induce changes in protein-protein interactions as seen for the phagocytic enzyme [32–34].

This study is aimed at providing the first quantitative description of the interactions taking place between NOX1 components in order to uncover the underlying mechanisms that are responsible for the observed stimulus-dependent increase in superoxide production. In particular we were interested in determining if the interaction between NOXO1 and p22phox is indeed constitutive and if, in the absence of the autoinhibitory region, there is any need for the tandem SH3 domains to adopt a superSH3 domain conformation.

Our data clearly indicate that both SH3 domains of NOXO1 are required for the interaction with p22phox, strongly suggesting that it will form a superSH3 domain. Importantly though, only very weak binding was observed between p22phox and a fragment of NOXO1 containing the tandem SH3 domains plus the C-terminal tail, implying that autoinhibitory interactions do indeed exist within NOXO1. Furthermore, unlike the phagocytic oxidase, complex formation between NOXO1 and NOX1 is relatively weak, indicating that the molecular details of this interaction must be significantly different from those between p47phox and p67phox.

Finally we show that there are differences in the level of autoinhibition between the human and murine proteins, highlighting that the two systems might be regulated by different mechanisms.

Results and Discussion

NOX1 forms a superSH3 domain that interacts tightly with p22phox

Our first aim was to establish if the tandem SH3 domains of NOXO1 co-operated in a manner similar to those of p47phox and form a superSH3 domain that contains a flexible ligand binding site for the accommodation of different targets with high affinity and specificity [22]. Isothermal titration calorimetry (ITC) was used to measure binding of the individual human or mouse NOXO1 SH3A and SH3B domains to the p22phox cytoplasmic domain. None of these titrations provided any evidence for complex formation, nor was there any binding between the isolated SH3 domains themselves (data not shown). This observation was confirmed using a fluorescently labelled p22phox-derived peptide and following changes in fluorescence intensity upon addition of increasing concentrations of human or mouse NOXO1 SH3A and SH3B domains. To ensure that lack of binding is not due to unfolding of the isolated SH3 domains, their structural integrity was confirmed by CD spectroscopy (data not shown). In contrast, the tandem SH3 domains of human and mouse NOXO1 bound tightly with affinities of 0.15 μM for human and 0.068 μM for mouse NOXO1 to the cytoplasmic domains (referred to as p22phox-C) of human and murine p22phox, respectively (Table 1 and Figure 2). These data firmly establish that the tandem SH3 domains of NOXO1 need to co-operate to form a single unit that tightly interacts with p22phox as previously observed in p47phox (Kd p47-p22phox: 0.19 μM, [22]).

In light of this high-affinity interaction between the tandem SH3 domains of NOX1 and p22phox it is rather surprising that a NOX1 fragment that lacks the PX (PhoX domain) domain is not capable anymore of co-localizing with NOX1 and p22phox at the plasma membrane as described by Cheng and colleagues [38]. This observation implies that the high affinity for p22phox must be diminished in the presence of additional sequences outside the tandem SH3 domains, possibly due to not yet identified autoinhibitory interactions.

The presence of the C-terminal tail of NOXO1 significantly weakens the interaction with p22phox

In the resting state, p47phox is prevented from binding to p22phox due to an intramolecular interaction between its tandem SH3 domains and the autoinhibitory region. This sequence is absent in human as well as mouse NOX1 (Figure 1A and B). To determine if other motifs are present in the C-terminal tail of NOX1 that may influence binding of the tandem SH3 domains to p22phox, ITC titrations were carried out with constructs harbouring the tandem SH3 domains plus the C-terminal portion of NOX1 (referred to as SH3AB-C). Indeed, the interaction between human SH3AB and p22phox was weakened over 100-fold to 17.5 μM in comparison to the tandem SH3 domains (Figure 3). Interestingly, this inhibitory effect of the C-terminal tail of NOXO1 is less pronounced in the mouse protein. Nevertheless,
binding to p22\textsuperscript{phox} is weakened by around 10-fold (K\textsubscript{d} = 0.78 \mu M; Figure 3 and Table 1). These results strongly suggest that autoinhibitory interactions do exist in both NOXO1 isoforms, but are more pronounced in the human protein. These data are particularly interesting in light of previous studies that showed that superoxide production by human NOX1 can be increased by stimulators such as PMA, while a similar increase could not be observed with the mouse proteins [32–34]. It is conceivable that the 0.78 \mu M tight interaction between murine NOXO1 and p22\textsuperscript{phox} is strong enough, even in the presence of inhibitory interactions with the C-terminal tail, to support full enzymatic activity, while the significantly weaker human complex (K\textsubscript{d} = 17.5 \mu M) requires a conformational change to adopt a fully active NOXO1-p22\textsuperscript{phox} complex conformation.

Close examination of the C-terminal tail of human NOXO1 reveals a region comprising a number of basic residues that is absent in the mouse protein (see Figure 1B) (residues 347–359, ERRPRQRGPRGR). To test whether this region might contribute to the stronger autoinhibition in human NOXO1, a peptide corresponding to this region was synthesized and binding to the tandem SH3 domains of NOXO1 with a shorter version of peptideA (K\textsubscript{d} = 0.5 \mu M) was able to bind with a similar affinity (data not shown). However, no binding was detected under the experimental conditions, suggesting that this is not the region responsible for the observed differences.

### The tandem SH3 domains of NOXO1 are involved in intramolecular interactions

SH3 domains classically bind to sequences harbouring a consensus PxxP motif. Such a motif is absent in the region responsible for autoinhibition in p47\textsuperscript{phox} but is present in the C-terminus of the protein. However, in the phagocytic enzyme this region mediates a very tight interaction with p67\textsuperscript{phox}. A homologous motif is found in the C-terminal regions of human and mouse NOXO1 and is similarly believed to be the target of the SH3 domain of NOXA1 (Figure 1B)[34,35]. To investigate if this region might be additionally involved in an intramolecular interaction with the tandem SH3 domains, a peptide corresponding to amino acids 319–347 of human NOXO1 (peptideA: TAPPTVPRPSGAIQSRCCVTTERALE) was titrated against the tandem SH3 domains as well as against the individual SH3\textsubscript{A} and SH3\textsubscript{B} domains of the human protein. A weak interaction with the tandem SH3 domains could be detected with a K\textsubscript{d} of around 50 \mu M but not with any of the individual domains (data not shown). Interestingly this affinity is similar to that previously measured for the interaction between the isolated PX and SH3 domains in p47\textsuperscript{phox}, which are believed to be engaged in an intramolecular interaction [39], consistent with a potential regulatory role. To gain further insight into the molecular details of this intramolecular interaction and to test the potential involvement of the conserved proline residues, which in the phagocytic enzyme are recognised by p67\textsuperscript{phox}, we mutated proline residues 323, 326 and 329 to alanine in construct SH3\textsubscript{A,B} (human) and tested the ability of this mutant protein to interact with p22\textsuperscript{phox}. Indeed, substitution of these proline residues strongly favoured the interaction with p22\textsuperscript{phox}, which now occurred with almost the same affinity to that of the isolated tandem SH3 domains (K\textsubscript{d} = 0.5 \mu M; Table 1). The importance of this region for autoinhibition is further supported by the titration of the tandem SH3 domains of NOXO1 with a shorter version of peptideA, which only contains the proline rich region (TAPPTVPRPSGAIQSRCCVTTERALE) and was able to bind with a similar affinity as the long version of peptideA (K\textsubscript{d} ~50 \mu M). These results convincingly show that intramolecular interactions do exist in NOXO1, which include its tandem SH3 domains and the proline-rich sequence located C-terminally to it that interfere with the interaction with p22\textsuperscript{phox}. Given the sequence conservation within the SH3 domains and proline-rich regions of human and mouse NOXO1 we do not understand at present why these autoinhibitory interactions are significantly more pronounced in human NOX1 and can only speculate that the length of the linker connecting the tandem SH3 domains and the proline-rich region, which is shorter in murine NOXO1, may be responsible for the observed differences.

### The interaction between NOXO1 and NOXA1 is weak

A previous study investigating the interaction between NOXO1 and NOXA1 showed that both proteins could be co-immunoprecipitated from COS cells [34], which led to the suggestion that they interacted in a manner similar to p47\textsuperscript{phox} and p67\textsuperscript{phox}. However, the data presented here clearly indicate that the proline-rich region of NOXO1 is engaged in an intramolecular interaction with its tandem SH3 domains and hence should not be available to

| Cell component | Syringe component | K\textsubscript{d} (x10\textsuperscript{-6} M) | \(\Delta H\) (kcal mole\textsuperscript{-1}) | T\textsubscript{M}S (kcal mole\textsuperscript{-1}) |
|----------------|------------------|-----------------|-----------------|-----------------|
| Human NOXO1    |                  |                 |                 |                 |
| SH3\textsubscript{A,B} | p22\textsuperscript{phox}C | 0.15±0.01 | −16.8±0.06 | −7.7 |
| SH3\textsubscript{A,B} | p22\textsuperscript{phox}C | 17.5±1.0 | −3.2±0.6 | 3.1 |
| SH3\textsubscript{A,B} triple mutant | p22\textsuperscript{phox}C | 0.53±0.4 | −8.1±0.5 | −0.058 |
| SH3\textsubscript{A} | p22\textsuperscript{phox}C | NB | | |
| SH3\textsubscript{B} | p22\textsuperscript{phox}C | NB | | |
| SH3\textsubscript{A} | SH3\textsubscript{B} | NB | | |
| Mouse NOXO1     |                  |                 |                 |                 |
| SH3\textsubscript{A,B} | p22\textsuperscript{phox}C | 0.068±0.01 | −12.9±0.03 | −3.3 |
| SH3\textsubscript{A,B} | p22\textsuperscript{phox}C | 0.78±0.06 | −7.1±0.05 | −0.29 |
| SH3\textsubscript{A} | p22\textsuperscript{phox}C | NB | | |
| SH3\textsubscript{B} | p22\textsuperscript{phox}C | NB | | |

All measurements were performed at 18 °C. The K\textsubscript{d} is given in units of 10\textsuperscript{-6} M. \(\Delta H\) and T\textsubscript{M}S are given in kcal mol\textsuperscript{-1} (1 kcal/mol=4.184 kJ/mol). The stoichiometry of complex formation for each binding site is N=1.0±0.1. No binding is indicated by NB.

doi:10.1371/journal.pone.0010478.t001

---

**Table 1.** Characterisation of intermolecular interactions between NOXO1 and p22\textsuperscript{phox}.
NOX1 Interactions

Figure 2. Characterisation of the interaction between the tandem SH3 domains of NOXO1 and peptides p22phox. Upper part shows the raw calorimetric data for the interaction of p22phoxC and human NOXO1 SH3AB. Lower part shows the integrated heat changes, corrected for heat of dilution, and fitted to a single site binding model. (■) Human p22phoxC titrated into human NOXO1 SH3AB (▲) Mouse p22phoxC titrated into mouse NOXO1 SH3AB.
doi:10.1371/journal.pone.0010478.g002

Figure 3. Characterisation of the interaction between NOXO1 SH3AB-E and p22phox. Upper part shows the raw calorimetric data for the interaction of mouse p22phoxC-NOXO1 SH3AB-E. Lower part shows the integrated heat changes, corrected for heat of dilution, and fitted to a single site binding model. (■) Human p22phoxC titrated into human NOXO1 SH3AB-E (▲) Mouse p22phoxC titrated into mouse NOXO1 SH3AB-E.
doi:10.1371/journal.pone.0010478.g003

NOX1. To gain further insight into the molecular basis of complex formation between these two proteins we measured binding of the human and mouse NOXA1-SH3 domains to either NOXO1 SH3AB-E construct by ITC. An interaction took place between the respective proteins, however, the complexes formed with 100-fold lower affinities (K_d = 7.2 μM for the human and K_d = 2.2 μM for the mouse proteins) than observed for their phagocytic counterpart (K_d = 20 nM, [26])(Figure 4A and Table 2). To test if this might be due to a competition between the tandem SH3 domains and NOXA1 for binding to the proline-rich motif we determined the affinity of this peptide for NOXA1-SH3 (human: K_d = 5.8 μM, mouse: K_d = 5.9 μM) was not significantly different from the affinity of the SH3AB-E construct, suggesting that the intramolecular interaction between the tandem SH3 domains and the proline-rich region has no influence on the interaction with NOXA1, which hence must recognize a different region. This conclusion is further supported by the observation that the short proline-rich motif-containing version of peptideA binds only with a very low affinity to NOXA1-SH3 (K_d > 70 μM; an exact determination of this dissociation constant was not possible due to a low heat change and the low affinity of the interaction). These observations are in contrast to a study by Yamamoto et al. who used GST pull-downs to investigate the NOXO1-NOXA1 interaction and found that wild-type NOXO1 failed to bind the SH3 domain of NOXA1, as suggested due to overlapping recognition motifs in the proline-rich region [40]. The reason for this discrepancy is not clear and we can only speculate that under the non-equilibrium conditions of pull-down assays one of the components may have been washed off.

In the phagocytic oxidase the p47phox-p67phox interaction is unusually strong (K_d of 20 nM) [25,26], due to the presence of two protein interfaces: contacts are made via the conserved PxxPxR motif (at amino acids 363–368), but also via an additional surface composed of residues 369–390 of p47phox, which fold into a helix-turn-helix (HTH) motif and pack against β-sheets 2, 3 and 4 of SH3B p67phox. Removal of this additional binding motif reduces the affinity for p67phox to 20 μM. Based on the data presented in this manuscript, we now suggest that the interaction between NOXO1 and NOXA1 relies solely on this additional binding
surface and does not include the proline-rich region. This scenario would be reminiscent of the behaviour of the SH3 domain of Pex13p, which binds to Pex14 in a conventional fashion via the recognition of a PxxP motif, while simultaneously interacting, via an independent surface, with a region in Pex15 that adopts an α-helical conformation [41,42]. Our model is supported by the fact that the key residues of p47phox in the HTH motif that make contact with p67phox (I374 and T382) are conserved in human and murine NOXO1. Structural studies are now required to fully unravel the details of these interactions.

In this study we provide evidence that the assembly of the NOX1 oxidase complex can be regulated through reversible protein-protein interactions. We show that the region C-terminal to the tandem SH3 domains of NOXO1 interferes with binding to p22phox and may thereby prevent the formation of a fully active oxidase complex in unstimulated cells. However, the inhibitory effect of the C-terminal tail is less pronounced in NOXO1 than in the homologous p47phox subunit of the phagocytic oxidase, and may explain why the NOX1 system is capable of producing low levels of superoxide, in a constitutive manner. Based on available data we propose the following model for the regulation of NOX1 activity: NOXO1 is constitutively associated with NOX1 and p22phox at the membrane, however, the complex with p22phox can exist in a high and low affinity state. In the resting state a low basal

**Figure 4. Characterisation of the interaction between NOXO1 and NOXA1.** (A) Upper part shows the raw calorimetric data for the interaction between human NOXA1 SH3 and NOXO1 SH3ab,e. Lower part shows the integrated heat changes, corrected for heat of dilution, and fitted to a single site binding model. (B) Human NOXA1 SH3 titrated into human NOXO1 SH3ab,e. (A) Mouse NOXA1 SH3 titrated into mouse NOXO1 SH3ab,e. (B) Upper part shows raw calorimetric data for the interaction of PeptideA and human NOXO1 SH3. Lower part shows the integrated heat changes, corrected for heat of dilution, and fitted to a single site binding model. (A) PeptideA titrated into human NOXO1 SH3 (A) PeptideA titrated into mouse NOXO1 SH3.

doi:10.1371/journal.pone.0010478.g004

**Table 2.** Characterisation of intermolecular interactions between NOXO1 and NOXA1.

| Cell component | Syringe component | K (x10^{-6} M) | ΔH (kcal mole^{-1}) | TΔS (kcal mole^{-1}) |
|----------------|-------------------|----------------|---------------------|---------------------|
| Human          |                   |                |                     |                     |
| NOXO1 SH3ab,e  | NOXA1 SH3         | 7.2±0.5        | −8.6±0.7            | −1.8               |
| NOXO1 SH3      | PeptideA          | 5.8±0.05       | −12.6±0.6           | −5.6               |
| NOXO1 SH3      | PeptideA-short    | >70            |                     |                     |
| Mouse          |                   |                |                     |                     |
| NOXO1 SH3ab,e  | NOXA1 SH3         | 2.2±0.05       | −10.1±0.8           | −3.0               |
| NOXO1 SH3      | PeptideA          | 5.9±0.7        | −7.6±0.3            | −0.64              |

All measurements were performed at 18°C. The Kd is given in units of 10^{-6} M. ΔH and TΔS are given in kcal mol^{-1} (1 kcal/mol=4.184 kJ/mol). The stoichiometry of complex formation for each binding site is N = 1.0±0.1.

doi:10.1371/journal.pone.0010478.t002
level of superoxide production is required for cellular processes, and this activity is maintained by the low affinity complex between NOXO1 and p22phox at the membrane. In this state the affinity of the tandem SH3 domains for p22phox would be too low to allow a constitutive interaction with the membrane-bound cytochrome and the presence of the PX domain is required to ensure membrane localization of NOXO1, hence explaining the recent observation by Cheng and Lambeth that NOXO1 is cytosolic in the absence of the PX domain [38]. Upon activation with stimulators such as PMA, NOXO1 becomes fully active and allows a high affinity interaction with p22phox, thereby giving rise to an increase in the level of superoxide production. At present, it is unclear how cycling of NOXO1 between these two states is regulated and what the molecular details of this active state are, but our data suggest that full activation will require disruption of the intramolecular interaction between the tandem SH3 domains and the proline-rich region. In the case of the phagocytic oxidase, it is the phosphorylation of multiple serine residues in the polybasic region of p47phox that induces these conformational changes. Equivalent phosphorylation sites are absent in NOXO1, suggesting that other mechanisms will regulate the interaction with p22phox. A recent report by Yamamoto et al. [40] showed that arachidonic acid could increase the interaction between NOXO1 and p22phox and it was suggested that this lipid may be a physiological stimulator. Other scenarios that have not been investigated yet, such as changes in protein-protein interactions induced by phosphorylation of NOXA1 or p22phox [43,44] could also be envisaged and we cannot rule out the possibility of involvement of an additional unknown component. Further studies are now required to shed more light on the regulation of superoxide production in the NOX1 system.

Materials and Methods

Plasmid construction

Mouse NOXO1 and NOXA1 cDNA were a kind gift from Dr. B. Banfi (Geneva University Hospital, Geneva, Switzerland), human NOXO1 and NOXA1 from Dr. T. Leto (National Institutes of Health, USA) and human p22phox was from Dr. M. C. Dinauer (Indiana University School of Medicine, Indiana, USA). Mouse p22phox was obtained from Life Technologies Inc (IMAG.E CLONE Id: 5100892). The NOXO1, NOXA1, p22phox full length proteins and fragments thereof were cloned into pGEX-6P1. Mutations were introduced by PCR-mediated site-directed mutagenesis using the Quikchange kit (Stratagene).

Protein overexpression and purification

Proteins were expressed in *Escherichia coli* strain BL21 STAR (Invitrogen) (see Figure 1A for complete list of constructs). Cell cultures were induced at an optical density (OD600) of 0.8 by the addition of 0.2 mM isopropyl-β-D-thiogalactopyranoside and grown for an additional 3 hours at 20°C. The cells were harvested and the pellets were stored frozen at −70°C. Cell pellets were thawed in buffer A (50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, with the addition of protease inhibitor tablets (Roche)). Cell membranes were disrupted by sonication on ice and supernatants obtained following a 1 hour centrifugation at 48,000×g. Recombinant GST-fusion proteins were purified by affinity chromatography on glutathione Sepharose 4B, washed with buffer A plus 500 mM NaCl and cleaved overnight in buffer A with PreScission Protease to remove the GST tag (Amersham Biosciences). Further purification was carried by gel filtration in buffer A on Superdex 75. The purity and identity of the proteins was confirmed by SDS/PAGE analysis (12 or 15% gels) and electrospray mass spectrometry. Synthetic peptides were prepared by P. Fletcher (NIMR) and Dr. W. J. Mawby (University of Bristol, UK).

Isothermal titration calorimetry

Complex formation between NOXO1, NOXA1 and p22phox fragments or peptides were measured by isothermal titration calorimetry using a MicroCal VP-ITC calorimeter (MicroCal Inc., Northampton, USA). All proteins were dialysed against ITC buffer (150 mM NaCl, 1 mM DTT and 50 mM HEPES, pH 7.4) and performed at 18°C. All peptides were dissolved in ITC buffer. Typically, 20–40 μM of protein in the cell was titrated by stepwise injections of a total of 200–300 μL of the ligand. Heats of dilution were determined by titrating protein or peptide into ITC buffer and subtracted from the raw ITC data prior to analysis with the software, Origin version 7.0, assuming a single-site binding model. Data were averaged over three to five experiments.

Fluorescence Intensity Titration

Fluorescence titrations were carried out using an ISS PC1 spectrofluorometer. All measurements were carried out at 20°C with excitation at 492 nm and emission at 525 nm. A solution containing fluorescein labelled peptide1 (0.5 μM) was prepared in ITC buffer. Binding measurements were performed by titrating increasing concentrations of NOXO1 SH3A or SH3B (1–50 μM) into this solution.

Acknowledgments

Mouse NOXO1 and NOXA1 cDNAs were a kind gift from Dr. B. Banfi (Geneva University Hospital, Geneva, Switzerland) and human NOXO1 and NOXA1 from Dr. T. Leto (National Institutes of Health, USA). We are grateful to Steve Howell (NIMR) for mass spectrometry, Pete Fletcher (NIMR) and Will Mawby (University of Bristol) for peptide synthesis, Steve Martin for recording of CD spectra and Phil Walker for help with protein purification.

Author Contributions

Conceived and designed the experiments: SD KR. Performed the experiments: SD. Analyzed the data: SD KR. Wrote the paper: KR.

References

1. Lambeth JD, Cheng G, Arnold RS, Edens WA (2000) Novel homologs of gp91phox. Trends Biochem Sci 25: 459–461.
2. Geiszt M, Leto TL (2004) The Nox family of NAD(P)H oxidases: host defense and beyond. J Biol Chem 279: 51715–51718.
3. Lambeth JD, Cheng G, Arnold RS, Edens WA (2000) Novel homologs of gp91phox. Trends Biochem Sci 25: S28–29.
4. Krause KH (2004) Tissue distribution and putative physiological function of NOX family NADPH oxidases. Jpn J Infect Dis 57: 1657: 1–22.
5. Bedark K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245–313.
6. Brown DI, Griendling KK (2005) NADPH oxidases in signal transduction. Free Radic Biol Med 47: 1239–1253.
7. Vignais PV (2002) The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 59: 1428–1459.
8. Vignais PV (2002) The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 59: 1428–1459.
9. Radic BI, Griendling KK (2005) NADPH oxidases in signal transduction. Free Radic Biol Med 47: 1239–1253.
10. Nauseef WM (2004) Assembly of the phagocyte NADPH oxidase. Histochem Cell Biol 122: 277–291.
11. Suh YA, Arnold RS, Lasegue B, Shi J, Xu X, et al. (1999) Cell transformation by the superoxide-generating oxidase Mox1. Nature 401: 79–82.

12. Cheng G, Cao Z, Xu X, van Meir EG, Lambeth JD (2001) Homologs of gp91phox: cloning and tissue expression of Nox3, Nox1, and Nox2. Gene 269: 131–140.

13. Geiszt M, Kopp JB, Varnai P, Leto TL. (2000) Identification of renox, an NADPH oxidase in kidney. Proc Natl Acad Sci U S A 97: 8010–8014.

14. Bantli B, Mohar G, Maturana A, Steger K, Hegedus B, et al. (2001) A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem 276: 37594–37601.

15. Lambeth JD (2002) Nox/Duox family of nicotinamide adenine dinucleotide (phosphate) oxidases.Curr Opin Hematol 9: 11–17.

16. Bokoch GM, Knaus UG (2003) NADPH oxidases: not just for leukocytes anymore? Trends Biochem Sci 28: 502–508.

17. Perris O, Wilson MI, Karathanasis D, Bravo J, Parold ME, et al. (2004) The role of phosphoinositides and phosphorylation in regulation of NADPH oxidase. Adv Enzyme Regul 44: 279–298.

18. Groemping Y, Rittinger K (2005) Activation and assembly of the NADPH oxidase: a structural perspective. Biochem J 386: 401–416.

19. El Benna J, Faust LP, Babior BM (1994) The phosphorylation of the respiratory burst oxidase component p47phox during neutrophil activation. Phosphorylation of sites recognized by protein kinase C and by proline-directed kinases. J Biol Chem 269: 23431–23436.

20. Leto TL, Adams AG, de Mendez I (1994) Assembly of the phagocyte NADPH oxidase: binding of Src homology 3 domains to proline-rich targets. Proc Natl Acad Sci U S A 91: 10650–10654.

21. Ago T, Nunnii H, Ito T, Sumimoto H (1999) Mechanism for phosphorylation-induced activation of the phagocyte NADPH oxidase protein p47phox. Triple replacement of serines 303, 304, and 328 with aspartates disrupts the SH3 domain-mediated intramolecular interaction in p47phox, thereby activating the oxidase. J Biol Chem 274: 33644–33653.

22. Groemping Y, Lapouge K, Smerdon SJ, Rittinger K (2003) Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell 113: 343–355.

23. Huang J, Kleinberg ME (1999). Activation of the phagocyte NADPH oxidase protein p47(phox). Phosphorylation controls SH3 domain-dependent binding to p22(phox). J Biol Chem 274: 19731–19737.

24. Yuzawa S, Suzuki NN, Fujioka Y, Ogura K, Sumimoto H, et al. (2004) A molecular mechanism for autoinhibition of the tandem SH3 domains of the PX domain, a target of the SH3 domain. Nat Struct Biol 8: 526–530.

25. Takeya R, Ueno N, Kami K, Taura M, Kohijima M, et al. (2003) Human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J Biol Chem 278: 25234–25246.

26. Ueyama T, Geiszt M, Leto TL (2008) Involvement of Rac1 in activation of multicomponent Nox1- and Nox3-based NADPH oxidases. Mol Cell Biol 28: 2160–2174.

27. Cheng G, Diebold BA, Hughes Y, Lambeth JD (2006) Nox1-dependent reactive oxygen generation is regulated by Rac1. J Biol Chem.

28. Suh YA, Arnold RS, Lasegue B, Shi J, Xu X, et al. (1999) Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. J Biol Chem 271: 3510–3513.

29. Kavahara T, Kawanou T, Yoshima-Kondo S, Takeya R, Sumimoto H, et al. (2004) Role of nicotinamide adenine dinucleotide phosphate oxidase 1 in oxidative burst response to Toll-like receptor 5 signaling in large intestinal epithelial cells. J Immunol 172: 3051–3058.

30. Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, et al. (2001) Hydrogen peroxide induces the cell growth and transformation caused by the mitogenic oxidase Nox1. J Biol Chem 276: 3510–3513.

31. Rokutani K, Kawahara T, Kawanou T, Tominaga K, Sekiya A, et al. (2006) NADPH oxidases in the gastrointestinal tract: a potential role of Nox1 in innate immune response and carcinogenesis. Antioxid Redox Signal 8: 1573–1582.

32. Geiszt M, Lekstrom K, Winta J, Leto TL. (2003) Proteins homologous to p47phox and p67phox support superoxide production by NADPH oxidase 1 in colon epithelial cells. J Biol Chem 278: 20006–20012.

33. Bantli B, Clark RA, Steger K, Krause KH (2003) Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem 278: 3510–3513.

34. Takeya R, Ueno N, Kami K, Taura M, Kohijima M, et al. (2003) Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J Biol Chem 278: 25234–25246.

35. Yamamoto A, Kami K, Takeya R, Sumimoto H, Kohsaka D (2001) Solution structure of the PX domain, a target of the SH3 domain. Nat Struct Biol 8: 526–530.

36. Yuzawa S, Suzuki NN, Fujioka Y, Ogura K, Sumimoto H, et al. (2004) A molecular mechanism for autoinhibition of the tandem SH3 domains of the PX domain, a target of the SH3 domain. Nat Struct Biol 8: 526–530.

37. Pires JR, Hong X, Brockmann C, Volkmann-Engert R, Schneider-Mergener J, et al. (2003) The ScPex13p SH3 domain exposes two distinct binding sites for the PX domain, a target of the SH3 domain. Mol Biol Cell 14: 4737–4742.

38. Hiroaki H, Ago T, Ito T, Sumimoto H, Kohsaka D (2001) Solution structure of the PX domain, a target of the SH3 domain. Nat Struct Biol 8: 526–530.

39. Yuzawa S, Suzuki NN, Fujioka Y, Ogura K, Sumimoto H, et al. (2004) A molecular mechanism for autoinhibition of the tandem SH3 domains of the PX domain, a target of the SH3 domain. Nat Struct Biol 8: 526–530.